may be used instead of a TNFi. In patients with severe psoriasis, an IL-12/23i or an IL-17i may be used instead of a TNFi. Tofacitinib may be used instead of a TNFi in patients preferring oral medication who do not have severe psoriasis. Switching to another OSM is recommended over adding another OSM to the current treatment (except in the case of apremilast). Adding another OSM (except apremilast) to current treatment may be considered if the patient has exhibited partial response to the